SERA icon

Sera Prognostics

1.71 USD
-0.07
3.93%
At close Jun 13, 4:00 PM EDT
After hours
1.68
-0.03
1.75%
1 day
-3.93%
5 days
10.32%
1 month
-27.23%
3 months
-57.67%
6 months
-80.16%
Year to date
-79.47%
1 year
-78.73%
5 years
-85.63%
10 years
-85.63%
 

About: Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

Employees: 64

0
Funds holding %
of 7,296 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

14% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 21

0.04% less ownership

Funds ownership: 55.17% [Q4 2024] → 55.13% (-0.04%) [Q1 2025]

3% less funds holding

Funds holding: 73 [Q4 2024] → 71 (-2) [Q1 2025]

10% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 10

49% less capital invested

Capital invested by funds: $147M [Q4 2024] → $74.4M (-$72.8M) [Q1 2025]

67% less call options, than puts

Call options by funds: $1K | Put options by funds: $3K

Research analyst outlook

We haven’t received any recent analyst ratings for SERA.

Financial journalist opinion

Negative
Zacks Investment Research
2 weeks ago
After Plunging 43.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sera Prognostics (SERA)
Sera Prognostics (SERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
After Plunging 43.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sera Prognostics (SERA)
Neutral
PRNewsWire
2 weeks ago
SERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
SALT LAKE CITY , May 29, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that members of the Sera team will participate in the following upcoming investor conferences: William Blair 45th Annual Growth Stock Conference Date: June 3 – 5, 20251X1 Meetings OnlyDoug Fisher, M.D., Strategic Advisor to Sera and former Chief Business Officer, will participate in meetings on Wednesday, June 4, 2025.
SERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
Neutral
PRNewsWire
1 month ago
SERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCE
SALT LAKE CITY , May 14, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the RBC Global Healthcare Conference on Wednesday, May 21, 2025, from 9:30 – 9:55 a.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss the company's latest achievements.
SERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCE
Positive
Zacks Investment Research
1 month ago
Down -30.54% in 4 Weeks, Here's Why Sera Prognostics (SERA) Looks Ripe for a Turnaround
Sera Prognostics (SERA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -30.54% in 4 Weeks, Here's Why Sera Prognostics (SERA) Looks Ripe for a Turnaround
Neutral
Seeking Alpha
1 month ago
Sera Prognostics Inc (SERA) Q1 2025 Earnings Call Transcript
Sera Prognostics Inc (NASDAQ:SERA ) Q1 2025 Earnings Conference Call May 7, 2025 5:00 PM ET Company Participants Peter DeNardo - IR, CapComm Partners Zhenya Lindgardt - President, CEO & Director Austin Aerts - CFO Conference Call Participants Dan Brennan - TD Cowen. Operator Good afternoon and welcome to the Sera Prognostics Conference Call to review First Quarter Fiscal Year 2025 Results.
Sera Prognostics Inc (SERA) Q1 2025 Earnings Call Transcript
Neutral
PRNewsWire
1 month ago
SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER
Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY , May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr.
SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER
Negative
Zacks Investment Research
1 month ago
Sera Prognostics, Inc. (SERA) Reports Q1 Loss, Misses Revenue Estimates
Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.25 per share a year ago.
Sera Prognostics, Inc. (SERA) Reports Q1 Loss, Misses Revenue Estimates
Neutral
PRNewsWire
1 month ago
SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
SALT LAKE CITY , May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights: Following release of full Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study results meeting primary success criteria, Sera is elevating engagement with payors and plan administrators.
SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
Neutral
PRNewsWire
1 month ago
Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2025 Financial Results on May 7, 2025
SALT LAKE CITY , April 24, 2025 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2025 financial results on Wednesday, May 7, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.
Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2025 Financial Results on May 7, 2025
Neutral
Seeking Alpha
2 months ago
Sera Prognostics Inc (SERA) Q4 2024 Earnings Call Transcript
Sera Prognostics Inc (NASDAQ:SERA ) Q4 2024 Earnings Conference Call March 19, 2025 5:00 PM ET Company Participants Peter DeNardo - IR, CapComm Partners Evguenia Lindgardt - President, CEO & Director Austin Aerts - CFO Conference Call Participants Dan Brennan - TD Cowen Margarate Boeye - William Blair Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review Fourth Quarter Fiscal Year 2024 Results. At this time, all participants are in listen-only mode.
Sera Prognostics Inc (SERA) Q4 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™